Loring Wolcott & Coolidge Fiduciary Advisors LLP Genmab A/S Transaction History

Loring Wolcott & Coolidge Fiduciary Advisors LLP

$11.1 Billion
Q2 2025

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2021 Nov 12, 2021	SELL	$41.55 - $48.72 $1,828 - $2,143	-44 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$32.88 - $44.57 $1,446 - $1,961	44 New	44 $2,000

Others Institutions Holding GMAB

# of Institutions

242

Shares Held

65.1M

Call Options Held

32.5K

Put Options Held

55K

Alliancebernstein L.P. New York, NY

10.7M
Shares

$358 Million
0.08% of portfolio
Orbis Allan Gray LTD Hamilton, D0

7.92M
Shares

$266 Million
1.07% of portfolio
Black Rock Inc. New York, NY

5.08M
Shares

$171 Million
0.0% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

3.57M
Shares

$120 Million
0.01% of portfolio
Arrowstreet Capital, Limited Partnership Boston, MA

3.45M
Shares

$116 Million
0.05% of portfolio

View Full List

About GENMAB A/S

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $22.1B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

More about GMAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Loring Wolcott & Coolidge Fiduciary Advisors LLP, based on Form 13F filings with the SEC.

News

Stay updated on Loring Wolcott & Coolidge Fiduciary Advisors LLP with notifications on news.

Account